Mobile

A RANDOMISED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, MULTICENTRE STUDY IN ASYMPTOMATIC HIV-INFECTED PATIENTS TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERATION OF ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-006821-15

A RANDOMISED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, MULTICENTRE STUDY IN ASYMPTOMATIC HIV-INFECTED PATIENTS TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERATION OF PF-00232798

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- Investigate the effects of 10-day monotherapy of PF-00232798 on viral load response in asymptomatic HIV-infected patients and to the assess dose-response relationship. - Assess the pharmacokinetics, safety and tolerability of PF-00232798 in HIV-infected patients.

Critère d'inclusion

  • Human Immunodeficiency Virus (HIV) infection

Liens